Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer

This study tests personalized mRNA cancer vaccines for people with pancreatic cancer that can be surgically removed. After surgery, the vaccine is custom-made using mutations unique to a patient's tumor (called neoantigens) to train the immune system to find and destroy remaining cancer cells. The goal is to reduce the chance of the cancer coming back. **You may be eligible if...** - You are 18 or older - You have pancreatic cancer that appears surgically removable on imaging - Your cancer is confirmed as pancreatic ductal adenocarcinoma after surgery - You have not had chemotherapy, radiation, or immunotherapy before for this cancer - Your general health status is good (ECOG 0 or 1) - Your expected survival is more than 12 weeks **You may NOT be eligible if...** - Your cancer cannot be completely removed surgically - You have had prior cancer treatment for pancreatic cancer - You have significant organ problems that would prevent safe participation - You have certain autoimmune or immune system conditions Talk to your doctor to see if this trial is right for you.